I know you're asking about developer tools - the main ones I use include:
* Webflow (in case the client needs something relatively unsophisticated)
* Django / HTMX / AlpineJS / Django Ninja (in case the client needs a full CRUD application with more powerful capabilities).
I also want to shamelessly plug - if you are looking to do freelance or contract work, and you want an easy way to manage the contract, engagements, milestones, and invoices, consider using withpartly.com.
I'm the founder and CEO, and looking for freelancers / contractors to play around with the alpha product (for free).
If you do opensource it, happy to help maintain it. This product would be helpful for my (fledgling) company, but would need to be self-hosted (use case is esignatures)
I'm creating software to make it easy for freelancers to manage their engagements, get paid, and handle all of the pieces of paper involved in that (NDA, IP assignment, etc). As part of that, I'm working with companies looking to hire contractors, specifically software engineers.
If you're looking to work with Series A / B companies as a software engineer for at least 10 hours a week (either in contract to hire or in permanent freelancer setups), please reach out! The main cost to you is you'll have to use my software and give me feedback on it. Thanks!
They are correlated until you admit to using them in the performance process. Then they’re far too easy to game and become useless. What we haven’t found is an adversary-resistant measure of productivity.
They are absolutely not correlated. Engineers often spend some quarters investigating and fixing scaling issues. This work does not need to a high number of locs.
If your work is merely adding some feature factory or bug fixes, maybe there is a correlation.
You are out of date. CRISPR is extremely effective in live patients, usually packaged in a virus or lipid nano particle.
While CRISPR is often used in cultured cells (eg for CAR T therapies) there are CRISPR therapeutics in live human patients today in phase 3 trials for sickle cell disease (among other indications).
The phase 3 trials you mention were probably for exa-cel, a therapy that involves removing the cells from the patient, editing them with CRISPR in the dish. Meanwhile you do myeloablation of the patient, aka destroy their bone marrow, then put in the repaired cells. The key here is: the application of CRISPR happens outside of the patient.
> Approximately 80% of the alleles at this locus were modified, with no evidence of off-target editing. After undergoing myeloablation, two patients - one with TDT and the other with SCD - received autologous CD34+ cells edited with CRISPR-Cas9 targeting the same BCL11A enhancer.
Similar (not the same) things have already been done multiple times for HIV patients who had to have their bone marrow destroyed for other reasons, generally leukemia (Düsseldorf Patient, Geneva Patient, London Patient, etc). They received transplants from donors that had mutations in CCR5, which prevents HIV. But you can't cure 40 million people living with HIV that way.
This therapy is extremely involved, expensive, and it also impacts the health of the patient (e.g. their entire immune memory is reset, they have to redo all their vaccinations). You don't destroy the bone marrow of someone due to no reason. Them requiring regular blood transfusions is a good reason, but them having to take antiretroviral drugs once per day is generally not seen as one.
The paper of this thread is about a single injection that does these CRISPR edits while inside the patient, without involving destruction of the bone marrow.
